Processing...
Clinical Trials for Rectal Cancer
Search
Search
There are 188 active trials for advanced/metastatic rectal cancer.
Click on a trial to see more information.
188 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Eligible patients are adults with locally advanced or metastatic solid tumors harboring a KRAS G12D mutation, who have progressed on or are intolerant to standard therapies and meet organ function and performance status criteria. The investigational drug TSN1611, an oral small molecule inhibitor targeting both active and inactive forms of KRAS G12D, is administered as monotherapy.
ClinicalTrials.gov ID: NCT06385925
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring documented KRAS mutations (excluding prior G12C inhibitor-treated G12C tumors), including NSCLC, CRC, pancreatic, and other KRAS-mutated cancers, who have progressed after standard therapies. Patients receive PF-07985045, a novel oral KRAS inhibitor, as monotherapy or in combination with chemotherapy, targeted agents, or immunotherapy, depending on cohort and tumor type.
ClinicalTrials.gov ID: NCT06704724
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including specific cohorts for EGFR-mutant or wild-type NSCLC, HNSCC, and metastatic CRC—to investigate AZD9592, a bispecific antibody-drug conjugate targeting EGFR and cMET, given alone or in combination with standard therapies such as osimertinib or 5-FU/bevacizumab/leucovorin. Key exclusions are active ILD/pneumonitis, untreated or unstable brain metastases, active infections, or significant cardiac disease.
ClinicalTrials.gov ID: NCT05647122
TrialFetch AI summary: Adult patients with advanced or metastatic solid tumors harboring a KRAS G12D mutation (including pancreatic, colorectal, or NSCLC), ECOG 0-1, and no prior KRAS G12D inhibitor exposure are eligible for treatment with INCB161734, a selective oral KRAS G12D inhibitor, given alone or in combination with standard therapies (e.g., gemcitabine/nab-paclitaxel, mFOLFIRINOX, cetuximab, or retifanlimab).
ClinicalTrials.gov ID: NCT06179160
TrialFetch AI summary: This trial enrolls adults with advanced, unresectable or metastatic colorectal cancer, non-small cell lung cancer, non-nasopharyngeal head and neck squamous cell carcinoma, or pancreatic ductal adenocarcinoma who have progressed on or are intolerant to standard therapies. Patients will receive PF-08046052/SGN-EGFRd2, a bispecific antibody that targets EGFR and conditionally activates γ9δ2-T cells to promote anti-tumor immune responses.
ClinicalTrials.gov ID: NCT05983133
TrialFetch AI summary: This trial enrolls adults with advanced, unresectable or metastatic solid tumors harboring any KRAS mutation who have progressed on or declined standard therapies; patients receive ALTA3263, an oral KRAS isoform-selective inhibitor that targets both active and inactive KRAS states and is designed to inhibit over 90% of known KRAS mutations, including G12D, G12V, and G12C. Prior KRAS inhibitor therapy is generally excluded.
ClinicalTrials.gov ID: NCT06835569
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS mutations (including NSCLC, CRC, and PDAC) who have progressed after standard therapies, testing the investigational oral panKRAS inhibitor PF-07934040 (blocks RAF binding to KRAS) as monotherapy and in combination with standard regimens. Eligible patients must have limited treatment options; certain arms allow first-line patients for combination therapies.
ClinicalTrials.gov ID: NCT06447662
TrialFetch AI summary: This trial enrolls adults with advanced, recurrent, or metastatic solid tumors (including platinum-resistant ovarian cancer, triple-negative breast cancer, squamous cell carcinoma of the anus or head and neck, non-small cell lung cancer, and uterine serous cancer) who have progressed on all standard therapies, to receive SMP-3124LP, a novel liposomal CHK1 inhibitor given by intravenous infusion. SMP-3124LP targets the DNA damage response pathway and is being assessed for safety, tolerability, and preliminary efficacy.
ClinicalTrials.gov ID: NCT06526819
TrialFetch AI summary: This trial enrolls adults with recurrent, unresectable, locally advanced, or metastatic solid tumors—including colorectal, pancreatic, NSCLC, ovarian cancer, mesothelioma, and others—that express mesothelin (MSLN) and have lost HLA-A*02 expression, who are heterozygous for HLA-A*02. Eligible patients receive a single infusion of A2B694, an autologous CAR T-cell therapy engineered with a logic-gated Tmod system to selectively target MSLN-positive, HLA-A*02-negative tumor cells.
ClinicalTrials.gov ID: NCT06051695
TrialFetch AI summary: This study enrolls adults with locally advanced unresectable or metastatic solid tumors harboring KRAS G12C mutations who have progressed on or are intolerant to standard therapy, to receive oral FMC-376, a novel dual inhibitor of both active and inactive KRAS G12C. Eligible patients must have ECOG 0-1.
ClinicalTrials.gov ID: NCT06244771